echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Leukemia: Preclinical evaluation of eltrombopag in the PDX model of myelodysplastic syndrome

    Leukemia: Preclinical evaluation of eltrombopag in the PDX model of myelodysplastic syndrome

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by bone marrow (BM) dysplasia, reduction of blood cells, recurrent genomic aberrations, and the susceptibility of the disease to develop into acute myeloid leukemia


    Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease characterized by bone marrow (BM) dysplasia, reduction of blood cells, recurrent genomic aberrations, and the susceptibility of the disease to develop into acute myeloid leukemia


    Although the current research on the molecular characterization of MDS has made great progress, the lack of preclinical models to solve functional problems has also made it difficult to convert the discovered mutation data into new treatment strategies




    In this study, the researchers mainly analyzed the effectiveness and safety of the thrombopoietin receptor agonist eltrombopag (Eltrombopag)


    Researchers mainly analyzed the effectiveness and safety of the thrombopoietin receptor agonist eltrombopag



    Preclinical evaluation using xenograft models derived from MDS patients

    Preclinical evaluation using xenograft models derived from MDS patients

    All in all, the results of the study reveal that the MDS PDX model can be used as a potential tool for testing new treatment concepts in MDS preclinical trials


    The MDS PDX model can be used as a potential tool for testing new treatment concepts in MDS preclinical trials



    Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.